Literature DB >> 29440378

Pathology after Chlamydia trachomatis infection is driven by nonprotective immune cells that are distinct from protective populations.

Rebeccah S Lijek1,2, Jennifer D Helble3, Andrew J Olive3,4, Kyra W Seiger2, Michael N Starnbach1.   

Abstract

Infection with Chlamydia trachomatis drives severe mucosal immunopathology; however, the immune responses that are required for mediating pathology vs. protection are not well understood. Here, we employed a mouse model to identify immune responses required for C. trachomatis-induced upper genital tract pathology and to determine whether these responses are also required for bacterial clearance. In mice as in humans, immunopathology was characterized by extravasation of leukocytes into the upper genital tract that occluded luminal spaces in the uterus and ovaries. Flow cytometry identified these cells as neutrophils at early time points and CD4+ and CD8+ T cells at later time points. To determine what draws these cells to C. trachomatis-infected tissue, we measured the expression of 700 inflammation-related genes in the upper genital tract and found an up-regulation of many chemokines, including a node of interaction between CXCL9/10/11 and their common receptor CXCR3. Either depleting neutrophils or reducing T-cell numbers by CXCR3 blockade was sufficient to significantly ameliorate immunopathology but had no effect on bacterial burden, demonstrating that these responses are necessary for mucosal pathology but dispensable for C. trachomatis clearance. Therapies that specifically target these host responses may therefore prove useful in ameliorating C. trachomatis-induced pathology without exacerbating infection or transmission.

Entities:  

Keywords:  CXCR3; Chlamydia; infection; neutrophils; pathology

Mesh:

Year:  2018        PMID: 29440378      PMCID: PMC5834673          DOI: 10.1073/pnas.1711356115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  17 in total

Review 1.  CXCR3 ligands in disease and therapy.

Authors:  Katrien Van Raemdonck; Philippe E Van den Steen; Sandra Liekens; Jo Van Damme; Sofie Struyf
Journal:  Cytokine Growth Factor Rev       Date:  2014-11-22       Impact factor: 7.638

Review 2.  Screening for Chlamydia trachomatis Infections in Women.

Authors:  Harold C Wiesenfeld
Journal:  N Engl J Med       Date:  2017-02-23       Impact factor: 91.245

3.  Genome sequences of Chlamydia trachomatis MoPn and Chlamydia pneumoniae AR39.

Authors:  T D Read; R C Brunham; C Shen; S R Gill; J F Heidelberg; O White; E K Hickey; J Peterson; T Utterback; K Berry; S Bass; K Linher; J Weidman; H Khouri; B Craven; C Bowman; R Dodson; M Gwinn; W Nelson; R DeBoy; J Kolonay; G McClarty; S L Salzberg; J Eisen; C M Fraser
Journal:  Nucleic Acids Res       Date:  2000-03-15       Impact factor: 16.971

4.  Histopathology of endocervical infection caused by Chlamydia trachomatis, herpes simplex virus, Trichomonas vaginalis, and Neisseria gonorrhoeae.

Authors:  N B Kiviat; J A Paavonen; P Wølner-Hanssen; C W Critchlow; W E Stamm; J Douglas; D A Eschenbach; L A Corey; K K Holmes
Journal:  Hum Pathol       Date:  1990-08       Impact factor: 3.466

5.  VACCINES. A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells.

Authors:  Georg Stary; Andrew Olive; Aleksandar F Radovic-Moreno; David Gondek; David Alvarez; Pamela A Basto; Mario Perro; Vladimir D Vrbanac; Andrew M Tager; Jinjun Shi; Jeremy A Yethon; Omid C Farokhzad; Robert Langer; Michael N Starnbach; Ulrich H von Andrian
Journal:  Science       Date:  2015-06-19       Impact factor: 47.728

Review 6.  Characteristics of the Chlamydia trachomatis species - immunopathology and infections.

Authors:  Irena Choroszy-Król Choroszy-Król; Magdalena Frej-Mądrzak; Agnieszka Jama-Kmiecik; Tamara Bober; Jolanta Jolanta Sarowska
Journal:  Adv Clin Exp Med       Date:  2012 Nov-Dec       Impact factor: 1.727

7.  Actin re-organization induced by Chlamydia trachomatis serovar D--evidence for a critical role of the effector protein CT166 targeting Rac.

Authors:  Jessica Thalmann; Katrin Janik; Martin May; Kirsten Sommer; Jenny Ebeling; Fred Hofmann; Harald Genth; Andreas Klos
Journal:  PLoS One       Date:  2010-03-25       Impact factor: 3.240

8.  CD4+ T cells are necessary and sufficient to confer protection against Chlamydia trachomatis infection in the murine upper genital tract.

Authors:  David C Gondek; Andrew J Olive; Georg Stary; Michael N Starnbach
Journal:  J Immunol       Date:  2012-08-01       Impact factor: 5.422

Review 9.  The balancing act of neutrophils.

Authors:  Bart W Bardoel; Elaine F Kenny; Gabriel Sollberger; Arturo Zychlinsky
Journal:  Cell Host Microbe       Date:  2014-05-14       Impact factor: 21.023

10.  Conditioning of naive CD4(+) T cells for enhanced peripheral Foxp3 induction by nonspecific bystander inflammation.

Authors:  Lucas J Thompson; Jen-Feng Lai; Andrea C Valladao; Tennille D Thelen; Zoe L Urry; Steven F Ziegler
Journal:  Nat Immunol       Date:  2016-01-11       Impact factor: 25.606

View more
  22 in total

1.  Antibody, but not B-cell-dependent antigen presentation, plays an essential role in preventing Chlamydia systemic dissemination in mice.

Authors:  Priyangi A Malaviarachchi; Miguel A B Mercado; Stephen J McSorley; Lin-Xi Li
Journal:  Eur J Immunol       Date:  2020-03-12       Impact factor: 5.532

2.  Early Colonization of the Upper Genital Tract by Chlamydia muridarum Is Associated with Enhanced Inflammation Later in Infection.

Authors:  Jennifer D Helble; Nicole V Reinhold-Larsson; Michael N Starnbach
Journal:  Infect Immun       Date:  2019-08-21       Impact factor: 3.441

3.  Analysis of complement deposition and processing on Chlamydia trachomatis.

Authors:  Mads Lausen; Mikkel Eggert Thomsen; Gunna Christiansen; Nichlas Karred; Allan Stensballe; Tue Bjerg Bennike; Svend Birkelund
Journal:  Med Microbiol Immunol       Date:  2020-11-18       Impact factor: 3.402

4.  Applying lessons from human papillomavirus vaccines to the development of vaccines against Chlamydia trachomatis.

Authors:  Kathryn M Frietze; Rebeccah Lijek; Bryce Chackerian
Journal:  Expert Rev Vaccines       Date:  2018-10-20       Impact factor: 5.217

5.  An endometrial organoid model of interactions between Chlamydia and epithelial and immune cells.

Authors:  Lee Dolat; Raphael H Valdivia
Journal:  J Cell Sci       Date:  2021-03-08       Impact factor: 5.285

Review 6.  Immunopathogenesis of genital Chlamydia infection: insights from mouse models.

Authors:  Jacob Dockterman; Jörn Coers
Journal:  Pathog Dis       Date:  2021-03-31       Impact factor: 3.951

7.  Stromal Fibroblasts Drive Host Inflammatory Responses That Are Dependent on Chlamydia trachomatis Strain Type and Likely Influence Disease Outcomes.

Authors:  Amber Leah Jolly; Sameeha Rau; Anmol K Chadha; Ekhlas Ahmed Abdulraheem; Deborah Dean
Journal:  mBio       Date:  2019-03-19       Impact factor: 7.867

8.  Reduced Uterine Tissue Damage during Chlamydia muridarum Infection in TREM-1,3-Deficient Mice.

Authors:  Bryan E McQueen; Avinash Kollipara; Clare E Gyorke; Charles W Andrews; Ashley Ezzell; Toni Darville; Uma M Nagarajan
Journal:  Infect Immun       Date:  2021-06-14       Impact factor: 3.441

Review 9.  T cell responses to Chlamydia.

Authors:  Jennifer D Helble; Michael N Starnbach
Journal:  Pathog Dis       Date:  2021-03-31       Impact factor: 3.166

10.  Effect of Time of Day of Infection on Chlamydia Infectivity and Pathogenesis.

Authors:  Stephanie R Lundy; Tarek Ahmad; Tankya Simoneaux; Ifeyinwa Benyeogor; YeMaya Robinson; Zenas George; Debra Ellerson; Ward Kirlin; Tolulope Omosun; Francis O Eko; Carolyn M Black; Uriel Blas-Machado; Jason P DeBruyne; Joseph U Igietseme; Qing He; Yusuf O Omosun
Journal:  Sci Rep       Date:  2019-08-06       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.